There has been a lot of progress in the development of MS therapy, since the first interferon for multiple sclerosis came on the market in the mid-90s. There are now almost 20 immunomodulatory agents approved. However, these can only be roughly assigned to four principles of action.
What is even more explosive is the great need for agents against progressive MS, also known as creeping or smoldering MS. So far, this can only be inadequately covered, although the first agents against the gradual increase in symptoms have already been approved. Things get interesting with new active substances in the pipeline. At the forefront is the (presumed) approval of the first “Brutinibs” (Tolebrutinib) in spring 2026. And there are even more active substances in phase 2 and 3 studies.
Also crucial is the recently initiated shift in perspective on the phases or types of the disease: The sooner multiple sclerosis is seen as a dynamic process in which creeping MS plays a role from the very beginning, the sooner one must counteract this circumstance with medication early in the disease. − Prof. Mathias Mäurer speaks in detail about the development of MS therapy in this video:
Please consider using the automated translation of YouTube. You can activate this function by clicking on the settings symbol and choosing subtitles.
This post was translated from German to English with the help of AI.
